昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301393 昊帆生物

已收盘 05-17 15:00:00

{"stockData":{"symbol":"301393","market":"SZ","secType":"STK","nameCN":"昊帆生物","latestPrice":48.33,"timestamp":1715929422000,"preClose":47.62,"halted":0,"volume":2699058,"delay":0,"floatShares":24727500,"shares":108000000,"eps":0.8567,"marketStatus":"已收盘","marketStatusCode":5,"change":0.71,"latestTime":"05-17 15:00:00","open":49.15,"high":50,"low":47.53,"amount":131000000,"amplitude":0.0519,"askPrice":48.34,"askSize":114,"bidPrice":48.33,"bidSize":32,"shortable":0,"etf":0,"ttmEps":0.8567,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":47.62,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":52.38,"lowLimit":42.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108000000,"pbRate":2.3,"roa":"--","roe":"1.34%","epsLYR":1.07,"committee":-0.413655,"marketValue":5220000000,"floatMarketCap":1195000000,"peRate":56.414147,"changeRate":0.0149,"turnoverRate":0.1092,"status":0},"requestUrl":"/m/hq/s/301393","defaultTab":"news","newsList":[{"id":"2436899563","title":"昊帆生物：公司在合成生物领域尚无布局，在AI制药方面暂无合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2436899563","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436899563?lang=zh_cn&edition=full","pubTime":"2024-05-17 17:05","pubTimestamp":1715936755,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物05月17日在投资者关系平台上答复投资者关心的问题。谢谢昊帆生物董秘：投资者您好，公司在合成生物领域尚无布局，在AI制药方面暂无合作。公司主要产品为多肽合成试剂，可广泛应用于含酰胺键的小分子化学药物和多肽药物的研发与生产中，具有良好的商业前景。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700031690.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435703675","title":"为扩大市场份额 昊帆生物(301393.SZ)拟约18亿元实施年产3010吨多肽合成试剂项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2435703675","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435703675?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:16","pubTimestamp":1715858200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊帆生物(301393.SZ)公告，公司与江苏淮安工业园区管理委员会于2024年5月16日签署了《投资框架协议》。公司拟在江苏淮安工业园区内投资建设年产3010吨多肽合成试剂项目，该项目总投资约18亿元，其中一期投资金额约10亿元。根据公告所示，项目总占地约370亩，一期建设用地约220亩，预留发展用地约150亩。四至范围为：南至张支路、东至楚盐路、北至盐北大道、西至陆集路。一期项目计划2024年12月开工，2026年12月投产。据悉，本次投资有利于促进公司中长期战略规划逐步落地，并进一步扩大市场份额与产业链业务发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122172.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435675163","title":"昊帆生物最新公告：拟18亿元投建年产3010吨多肽合成试剂项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2435675163","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435675163?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:11","pubTimestamp":1715857879,"startTime":"0","endTime":"0","summary":"昊帆生物公告，拟在江苏淮安工业园区内投资建设年产3010吨多肽合成试剂项目，该项目总投资约18亿元，其中一期投资金额约10亿元。一期项目投资金额约10亿元，计划2024年12月开工，2026年12月投产。二期项目将在一期项目建成后根据市场需求、公司资金情况等另行商定。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600029175.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435636825","title":"昊帆生物(301393.SZ)拟10股派2.5元 于5月23日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2435636825","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435636825?lang=zh_cn&edition=full","pubTime":"2024-05-15 19:17","pubTimestamp":1715771821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊帆生物(301393.SZ)公告，公司2023年年度权益分派拟：向全体股东按每10股派发现金股利2.50元(含税)。除权除息日为：2024年5月23日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121629.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433966122","title":"减肥药概念盘中拉升，昊帆生物涨10.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433966122","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433966122?lang=zh_cn&edition=full","pubTime":"2024-05-07 10:58","pubTimestamp":1715050717,"startTime":"0","endTime":"0","summary":"05月07日，减肥药概念盘中拉升，截至10点58分，减肥药概念整体指数上涨1.08%，报939.210点。从个股上来看，该概念的成分股中，昊帆生物涨10.77%，争光股份、博瑞医药、德展健康涨幅居前。从资金上来看，截止发稿，减肥药概念主力净流入为-1.41亿，其中博瑞医药受到资金热捧，主力净流入4081.63万；拉长时间线来看，该板块近20日主力资金净流入-19.34亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507105837861eb5fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240507105837861eb5fd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433136449","title":"昊帆生物：公司目前没有该领域相关产品和布局，公司在该领域也没有相应的规划及准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2433136449","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433136449?lang=zh_cn&edition=full","pubTime":"2024-05-06 17:11","pubTimestamp":1714986664,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物(301393)05月06日在投资者关系平台上答复投资者关心的问题。投资者：董秘，您好！请问贵司有合成生物相关产品或布局吗？在合成生物学领域有何规划及准备。昊帆生物董秘：投资者您好，公司目前没有该领域相关产品和布局，公司在该领域也没有相应的规划及准备，感谢您的关注。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600018164.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433363445","title":"昊帆生物涨20.00%，开源证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433363445","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433363445?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:41","pubTimestamp":1714984881,"startTime":"0","endTime":"0","summary":"今日昊帆生物涨20.00%，收盘报52.45元。2024年4月11日，开源证券研究员余汝意,汪晋发布了对昊帆生物的研报《公司信息更新报告：业绩阶段性承压，自有产能逐步落地赋能中长期发展》，该研报对昊帆生物给出“买入”评级。研报中预计2024-2026年归母净利润为1.17/1.50/1.89亿元，EPS为1.08/1.39/1.75元，当前股价对应PE为39.2/30.7/24.3倍，鉴于多肽药物领域快速发展以及公司处于行业龙头地位，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600015429.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433626494","title":"异动快报：昊帆生物（301393）5月6日10点4分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2433626494","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433626494?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:05","pubTimestamp":1714961129,"startTime":"0","endTime":"0","summary":"证券之星5月6日盘中消息，10点4分昊帆生物触及涨停板。目前价格52.45，上涨20.0%。其所属行业生物制品目前上涨。4月30日的资金流向数据方面，主力资金净流入287.07万元，占总成交额3.34%，游资资金净流入393.76万元，占总成交额4.58%，散户资金净流出680.83万元，占总成交额7.91%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600003638.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430370552","title":"图解昊帆生物一季报：第一季度单季净利润同比减17.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430370552","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430370552?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:57","pubTimestamp":1714067840,"startTime":"0","endTime":"0","summary":"证券之星消息，昊帆生物2024年一季报显示，公司主营收入9122.97万元，同比下降27.14%；归母净利润2982.88万元，同比下降17.8%；扣非净利润2576.98万元，同比下降24.12%；负债率3.44%，财务费用-1394.11万元，毛利率38.03%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600002684.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430947759","title":"昊帆生物(301393.SZ)发布一季度业绩，净利润2982.88万元，同比减少17.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430947759","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430947759?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:23","pubTimestamp":1714040612,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊帆生物(301393.SZ)发布2024年第一季度报告，该公司于期间实现营业收入9122.97万元，同比减少27.14%;归属于上市公司股东的净利润2982.88万元，同比减少17.8%;归属于上市公司股东的扣除非经常性损益的净利润2576.98万元，同比减少24.12%;基本每股收益0.28元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110142.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430981420","title":"昊帆生物涨6.13%，开源证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430981420","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430981420?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:20","pubTimestamp":1714033251,"startTime":"0","endTime":"0","summary":"今日昊帆生物涨6.13%，收盘报41.74元。2024年4月11日，开源证券研究员余汝意,汪晋发布了对昊帆生物的研报《公司信息更新报告：业绩阶段性承压，自有产能逐步落地赋能中长期发展》，该研报对昊帆生物给出“买入”评级。研报中预计2024-2026年归母净利润为1.17/1.50/1.89亿元，EPS为1.08/1.39/1.75元，当前股价对应PE为39.2/30.7/24.3倍，鉴于多肽药物领域快速发展以及公司处于行业龙头地位，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500032188.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426766179","title":"昊帆生物上市首年业绩变脸","url":"https://stock-news.laohu8.com/highlight/detail?id=2426766179","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2426766179?lang=zh_cn&edition=full","pubTime":"2024-04-10 00:21","pubTimestamp":1712679660,"startTime":"0","endTime":"0","summary":"　　昊帆生物上市首年的成绩单已于4月9日对外披露，2023年，公司营业收入、归属净利润双双下滑。业绩疲软之下，昊帆生物股价也不断走低，虽然曾凭借减肥药概念迎来一波上涨行情，但整体看，公司上市以来股价已跌近六成。　　昊帆生物在上市首年营业收入、归属净利润出现双降。　　资料显示，昊帆生物于2023年7月12日登陆创业板。　　而在上市前，昊帆生物归属净利润已连续两年上涨，其中2021年归属净利润同比增长率高达175.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-04-10/doc-inarhhxn1832711.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-10/doc-inarhhxn1832711.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425896110","title":"昊帆生物(301393.SZ)发布2023年度业绩，净利润9897.38万元，下降23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425896110","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2425896110?lang=zh_cn&edition=full","pubTime":"2024-04-08 18:23","pubTimestamp":1712571780,"startTime":"0","endTime":"0","summary":"昊帆生物发布2023年年度报告，报告期内，公司实现营业收入3.89亿元，同比下降13.11%。实现归属于上市公司股东的净利润9897.38万元，同比下降23.50%。基本每股收益为1.07元。拟向全体股东每10股派发现金红利2.50元(含税)。分产品来看，多肽合成试剂销售金额为3.02亿元，同比下降14.06%，通用型分子砌块销售金额为7,418.69万元，同比增长8.87%，蛋白质试剂销售金额为964.27万元，同比下降61.79%，脂质体与脂质纳米粒药用试剂等新产品销售金额为339.06万元，同比增长6.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarcpan5057501.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-08/doc-inarcpan5057501.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2407006653","title":"概念掘金 | 国内首个！口服“减肥药”在华获批上市，哪些公司有望受益？","url":"https://stock-news.laohu8.com/highlight/detail?id=2407006653","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2407006653?lang=zh_cn&edition=full","pubTime":"2024-01-29 10:21","pubTimestamp":1706494903,"startTime":"0","endTime":"0","summary":"中国GLP-1减重市场有望突破千亿","market":"us","thumbnail":"https://img3.gelonghui.com/cde03-d1a76e07-baae-4601-a193-b8aac34cc6d5.jpg?guru_height=852&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/cde03-d1a76e07-baae-4601-a193-b8aac34cc6d5.jpg?guru_height=852&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/689324","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-07-12","address":"江苏省苏州市虎丘区高新区长亭路1号","stockEarnings":[{"period":"1week","weight":-0.1119},{"period":"1month","weight":0.2421},{"period":"3month","weight":0.1485},{"period":"6month","weight":-0.3417},{"period":"1year","weight":-0.2859},{"period":"ytd","weight":-0.1946}],"companyName":"苏州昊帆生物股份有限公司","boardCode":"AI0026","perCapita":"1988股","boardName":"化学原料和化学制品制造业","registeredCapital":"10800万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　苏州昊帆生物股份有限公司主营业务为多肽合成试剂的研发、生产与销售。主要产品包括缩合试剂、保护试剂、手性消旋抑制试剂、蛋白质交联剂、蛋白质还原剂、通用型分子砌块、脂质体与脂质纳米粒药用试剂等。公司可为下游客户提供近150种结构新颖、质量优异的多肽合成试剂产品，是全球为数不多的能够提供全系列多肽合成试剂研发与产业化的公司之一，并在HATU、HBTU、TBTU、PyBOP等多个合成工艺更为先进、产品附加值更高、竞争壁垒更高的磷正离子型和脲正离子型产品领域处于市场主导地位。","serverTime":1715971063263,"listedPrice":67.68,"stockholders":"12434人(较上一季度减少28.83%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊帆生物,301393,昊帆生物股票,昊帆生物股票老虎,昊帆生物股票老虎国际,昊帆生物行情,昊帆生物股票行情,昊帆生物股价,昊帆生物股市,昊帆生物股票价格,昊帆生物股票交易,昊帆生物股票购买,昊帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}